CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas

Genes Chromosomes and Cancer

Volumn 25, Issue 4, 1999, Pages 339-348

  Holland, Elizabeth A ^a   Schmid, Helen ^a   Kefford, Richard F ^a   Mann, Graham J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN P16;

ARTICLE; CARCINOGENESIS; DNA SEQUENCE; FAMILY HISTORY; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL;

EID: 0032784037     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199908)25:4<339::AID-GCC5>3.0.CO;2-H     Document Type: Article

References (71)

1. Aitken JF, Duffy DL, Green A, Youl P, MacLennan R, Martin NG. 1994. Heterogeneity of melanoma risk in families of melanoma patients. Am J Epidem 140:961-973.
2. Bergman W, Gruis NA, Sandkuijl LA, Frants RR. 1994. Genetics of seven Dutch familial atypical multiple mole-melanoma syndrome families: a review of linkage results including chromosomes 1 and 9. J Invest Dermatol 103:122s-125s.
3. Borg A. Johansson U, Johannsson O, Hakansson S, Westerdahl J, Masback A, Olsson H, Ingvar C. 1996. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 56:2497-2500.
4. INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. Molec Cell 1:421-431.
5. Cannon Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, Olopade OI, Diaz MO, Kwiatkowski DJ, Piepkorn MW, Zone JJ, Skolnick MH. 1992. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258:1148-1152.
6. Cannon Albright LA, Goldgar DE, Neuhausen S, Gruis NA, Anderson DE, Lewis CM, Jost M, Tran TD, Nyguen K, Kamb A, Weaver-Feldhaus J, Meyer LJ, Zone JJ, Skolnick MH. 1994. Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. Genomics 23:265-268.
7. Ciotti P, Strigini P, Bianchi-Scarra G. 1996. Familial melanoma and pancreatic cancer. N Engl J Med 334:469-470.
8. Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, Brinkley P, Price S, Webster KR. 1997. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol Chem 272:18869-18874.
9. ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Nat Acad Sci 93:8541-8545.
10. Flores JF, Walker GJ, Glendening JM, Haluska FG, Castresana JS, Rubio MP, Pastorfide GC, Boyer LA, Kao WH, Bulyk ML, Barnhill RL, Hayward NK, Housman DE, Fountain JW. 1996. Loss of the p16INK4a and p15INK4b genes as well as neighboring 9p21 markers in sporadic melanoma. Cancer Res 56:5023-5032.
11. Flores JF, Pollock PM, Walker GJ, Glendening JM, Lin AH-T. Palmer JM, Walters MK, Hayward NK, Fountain JW. 1997. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 15:2999-3005.
12. Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH Jr, Tucker MA. 1994. Linkage of cutaneous malignant melanoma/ dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 54:489-196.
13. Gruis N, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR. 1995. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet 10:351-353.
14. Guldberg P, Kirkin AF, Gronhaek K, Straten PT, Ahrenkiel V, Zeuthen J. 1997. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer 72:780-783.
15. Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop D, Newton-Bishop J. 1997. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Molec Genet 6:2061-2067.
16. Hayashi K. 1991. PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. PCR Methods Applic 1:34-38.
17. Holland EA, Beaton SC, Edwards BG, Kefford RF, Mann GJ. 1994. Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. Oncogene 9:1361-1365.
18. Holland EA, Beaton SC, Becker TM, Grulet OMC, Peters B, Rizos H, Kefford RF, Mann GJ. 1995. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11:2289-2294.
19. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC. 1994. Germline p16 mutations in familial melanoma. Nat Genet 8: 15-21.
20. Ingvar C, Borg A, Olsson H, Sandberg T, Borgqvist R. Westerdahl J, Masback A, Nilsson K, Jonsson N. 1997. Special histopathology in germline CDKn2a/p16 mutated melanoma. Melanoma Res 7:S134.
21. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP. 1995. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376:313-320.
22. INK4d. FEBS Lett 401:127-132.
23. Kamb A, Gruis NA, Weaver Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH. 1994a. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
24. Kamb A, Shattuck-Eidens D, Eeles R, Lui Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA. 1994b. Analysis of the p16 gene (CDKN2) as a candidate for the melanoma susceptibility locus. Nat Genet 8:22-26.
25. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Nat Acad Sci USA 95:8292-8297.
26. Koh J, Enders GH, Dynlacht BD, Harlow E. 1995. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506-510.
27. INK4a) gene in microdissected sporadic primary melanomas. Int J Cancer 75:193-198.
28. Liggett WHJ, Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D. 1996. p16 and p16b are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 56:4119-4123.
29. INK4 CDK inhibitory activity. Int J Cancer 66:249-254.
30. INK4 mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11:405-412.
31. ARF. Genes Chromosomes Cancer 19:52-54.
32. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D. 1999. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:1-5.
33. Ink4d. Nature 389:999-1003.
34. MacGeoch C, Bishop JA, Bataille V, Bishop DT, Fristhaut AM, Meloni R, Cuzick J, Pinney E, Spurr NK. 1994. Genetic heterogeneity in familial malignant melanoma. Hum Molec Genet 3:2195-2200.
35. MacKie RM, Andrew N, Lanyon WG, Connor JM. 1998. CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. J Investig Dermatol 111:269-272.
36. INK4A transcript. Cancer Res 55:2995-2997.
37. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ. 1998. CDKN2A mutations in multiple primary melanomas. N Engl J Med 338:879-887.
38. Nancarrow DJ, Mann GJ, Holland EA, Walker GJ, Beaton SC, Walters MK, Luxford C, Palmer JM, Donald JA, Weber JL, Fountain JW, Kefford RK, Hayward NK. 1993. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 53:936-942.
39. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
40. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, Huebner K. 1994. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res 54:5269-5272.
41. Ohta M, Berd D, Shimizu M, Nagai H, Cotticelli MG, Mastrangelo M, Shields JA, Shields CL, Croce CM, Huebner K. 1996. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer 65:762-767.
42. INK4A in human cancer. Proc Nat Acad Sci USA 91:11045-11049.
43. CDKN2 associated with familial melanoma. Molec Cell Biol 16:3844-3852.
44. Platz A, Ringborg U, Lagerlof B, Lundqvist E, Sevigny P, Inganas M. 1996a. Mutational analysis of the CDKN2A gene in metastases from patients with cutaneous malignant melanoma. Br J Cancer 73:344-348.
45. Platz A, Sevigny P, Norberg T, Ring P, Lagerlof B, Ringborg U. 1996b. Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. Br J Cancer 74:936-941.
46. Platz A, Hansson J, Mansson-Brahme E, Lagerlof B, Linder S, Lundqvist E, Sevigny P, Inganas M, Ringborg U. 1997. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 89:697-702.
47. Pollock PM, Hayward NK. 1997. Evidence of founders in melanoma families carrying M53I and 24BP duplication mutations in CDKN2A. Melanoma Res 7:S135.
48. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
49. Puig S, Ruiz A, Lazaro C, Castel T, Lynch M, Palou J, Vilalta A, Weissenbach J, Mascaro J-M, Estiville X. 1995. Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. Am J Hum Genet 57:395-402.
50. ARF. Proc Nat Acad Sci 94:669-673.
51. INK4 function. Nat Genet 10:114-116.
52. Reymond A, Brent R. 1995. p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 11:1173-1178.
53. 1NK4a and p16b transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations. Oncogene 15:515-523.
54. Ruiz A, Puig S, Lynch M, Castel T, Estivill X. 1998. Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma. Int J Cancer 76:312-316.
55. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY. Cold Spring Harbour Laboratory Press.
56. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, the French Familial Melanoma Study Group, Benard J, Bressac-de Paillerets B. 1998. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Molec Genet 7:209-216.
57. Spruck CH, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin M-F, Gonzales F, Tsai YC, Jones PA. 1994. p16 gene in uncultured tumours. Nature 370:183-184.
58. Stone S, Jiang P, Dayananath P, Tavtigian SV, Katcher H, Parry D, Peters G and Kamb A. 1995a. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 55:2988-2994.
59. Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A. 1995b. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 11:987-991.
60. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17:5001-5014.
61. INK4A: structural characterisation of wild-type and mutant proteins by NMR and circular dichroism. Biochem 35:9475-9487.
62. Tsao H, Benoit E, Sober AJ, Thiele C, Haluska FG. 1998. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res 58:109-113.
63. Walker GJ, Hussussian CJ, Flore JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW. 1995. Mutations of the CDKN2/p16(INK4) gene in Australian melanoma kindreds. Hum Molec Genet 4:1845-1852.
64. Whelan AJ, Bartsch D, Goodfellow PJ. 1995. A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333:975-977.
65. Wick ST, Dubay MM, Imanil I, Brizuela L. 1995. Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16. Oncogene 11:2013-2019.
66. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann Hieb K, De Plaen E, Hankeln T, Meyer zum Buschenfelde K-H, Beach D. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284.
67. INK4a tumour suppressor protein. Cancer Res 55:2503-2506.
68. Yang R, Serrano M, Slater J, Leung E, Koeffler HP. 1996. Analysis of p16INK4a and its interaction with CDK4. Biochem Biophys Res Comm 218:254-259.
69. INK4A proteins encoded by tumour-derived alleles. J Biol Chem 271: 28734-28737.
70. Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degredation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.
71. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopli NC. 1996. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99.